• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tempest Therapeutics Inc.

    1/21/26 9:27:23 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tempest Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    87978U207

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    87978U207


    1Names of Reporting Persons

    SABBY MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    492,223.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    492,223.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    492,223.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    87978U207


    1Names of Reporting Persons

    Hal Mintz
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    492,223.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    492,223.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    492,223.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87978U207


    1Names of Reporting Persons

    Sabby Volatility Warrant Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    492,223.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    492,223.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    492,223.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tempest Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CALIFORNIA, 94005
    Item 2. 
    (a)Name of person filing:

    Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz
    (b)Address or principal business office or, if none, residence:

    Sabby Volatility Warrant Master Fund, Ltd. c/o Captiva (Cayman) Ltd Governors Square, Bldg 4, 2nd Floor 23 Lime Tree Bay Avenue P.O. Box 32315 Grand Cayman KY1-1209 Cayman Islands Sabby Management, LLC 1011 Links Dr. Miami Beach, FL 33109 Hal Mintz c/o Sabby Management, LLC 1011 LInks Dr. Miami Beach, FL 33109
    (c)Citizenship:

    Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    87978U207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    abby Volatility Warrant Master Fund, Ltd. - 492,223 Sabby Management, LLC - 492,223 Hal Mintz - 492,223
    (b)Percent of class:

    Sabby Volatility Warrant Master Fund, Ltd. - 9.9% Sabby Management, LLC - 9.9% Hal Mintz - 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    492,223

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    492,223

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SABBY MANAGEMENT, LLC
     
    Signature:/s/ Robert Grundstein
    Name/Title:COO
    Date:01/21/2026
     
    Hal Mintz
     
    Signature:/S/ HAL MINTZ
    Name/Title:HAL MINTZ
    Date:01/14/2026
     
    Sabby Volatility Warrant Master Fund, Ltd.
     
    Signature:/s/ Harry Thompson
    Name/Title:Harry Thompson
    Date:01/21/2026
    Get the next $TPST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by Scotiabank

    Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

    4/10/25 8:50:49 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

    4/10/25 8:03:29 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced the closing of its previously announced registered direct offering priced at the market under Nasdaq rules for the purchase and sale of 1,172,414 shares of its common stock (or common stock equivalents), at an offering price of $3.625 per share of common stock (or common stock equivalent). Additionally, in a concurrent private placement, the Company issued and sold short-term unregistered warrants to purchase up to an aggregate of 1,172,414 shares of

    11/26/25 4:05:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

    BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,172,414 shares of its common stock (or common stock equivalents), at an offering price of $3.625 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue and sell short-term unr

    11/25/25 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    SEC Filings

    View All

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    1/28/26 4:05:33 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tempest Therapeutics Inc.

    SCHEDULE 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    1/21/26 9:27:23 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    1/9/26 4:15:35 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pellizzari Christine A

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    1/28/26 4:30:06 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nichol Geoffrey

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    1/28/26 4:30:08 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Raab Michael

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    1/28/26 4:30:08 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/2/24 4:15:14 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

    BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John

    9/18/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

    BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. "Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,"

    8/21/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Extends Limited Duration Stockholder Rights Plan

    BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

    10/10/24 7:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

    21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

    6/20/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    5/13/24 4:54:01 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    2/14/24 6:49:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care